Gerald Commissiong is President & CEO Todos Medical Ltd. (OTCQB: TOMDF), in addition to Amarantus Bioscience Holdings, Inc. and interim-CEO of Breakthrough Diagnostics, Inc., Todos’ joint venture with Amarantus. Mr. Commissiong has been responsible for Amarantus’ strategic transactions, licensing, research collaborations, mergers & acquisitions in therapeutics and diagnostics, as well as fund raising, having raised over of $50 million since inception. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.
Clinical Dx Showcase:
Todos Medical is a commercial in vitro diagnostics company focused on developing novel, convenient tests for the early detection of COVID-19, cancer and neurodegenerative disorders.
Tollovir: Phase II Covid-19 Antiviral Drug Candidate
Tollovir: Phase II, Antiviral 3CL-Protease Inhibitor for Hospitalized Covid-19 Patients
Session Abstract – PMWC 2022 Silicon Valley
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative